Sofinnova Partners grows crossover fund by 63% to €725m, eyes European life sciences funding gap
Monday, November 16, 2026 · first reported by AltAssets and 2 others
Sofinnova Partners has closed Sofinnova Crossover II at €725 million ($815 million per HedgeCo), above its original target. AltAssets puts the fund at 63% larger than its predecessor.
The vehicle will hold about 15 companies, mainly European clinical-stage biopharma and medtech businesses needing capital to reach commercialization, with some investments in the United States and elsewhere. Partner Kinam Hong said about 80% will go to Europe. Investing has begun, with Neurent Medical, Hemab Therapeutics and CellCentric among the first holdings.
- Size
- €725M (≈$789M)
- Stage
- Target
- Asset class
- Private equity, Venture
- Geography
- Europe
In the data This close in the fund closes table · Every Sofinnova Partners close
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
See an error?
Coverage
3 sources- Gemspring Capital more than doubles buyout fund size with $3.5bn hard-cap close in under three monthsAltAssets
- KKR-led consortium pays $10b in cash for majority stake in Sempra Infrastructure PartnersIREI
- ASR Real Assets considers higher return target for €2.6bn farmland fundAgri Investor
- Diamondback nears $5bn acquisition of EnCap-backed Permian assetsPrivate Equity Wire
- HCMC Boosts venture Fund, 10 VIFC Members target $2.7 billionVietcetera
- Mubadala and Centerbridge acquire Canaccord Wealthpaperjam.lu +2
Got news? Send it to us →